PHCEF - PharmaCielo Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
2.4200
-0.0200 (-0.82%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close2.4400
Open2.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.4000 - 2.4750
52 Week Range1.9000 - 9.9750
Volume18,466
Avg. Volume48,991
Market Cap239M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PharmaCielo Announces Receipt of CAD$3.9 Million Secured Loan Repayment
    CNW Group

    PharmaCielo Announces Receipt of CAD$3.9 Million Secured Loan Repayment

    TORONTO , Dec. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced that Creso Pharma Limited ("Creso") (CPH.AX) has repaid in full, all principal and interest owing to the Company in the amount of approximately CAD$3.9 million under the secured bridge loan by PharmaCielo to Creso that was made pursuant to an amendment to Creso's existing loan deed, originally entered into with an arm's length party to Creso on April 26, 2019 (the "Secured Bridge Loan").

  • /C O R R E C T I O N from Source -- PharmaCielo Ltd./
    CNW Group

    /C O R R E C T I O N from Source -- PharmaCielo Ltd./

    /C O R R E C T I O N from Source -- PharmaCielo Ltd./

  • PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019
    CNW Group

    PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019

    Well capitalized with cash and short-term investments of $20.7 million as of September 30, 2019 . Nearing completion of extraction and processing center ("RTC"), which will expand the Company's extraction capacity to 265 tonnes of dried flower per year ( processed equivalent volume of 28,900 kg of cannabis oil per year). TORONTO and RIONEGRO, Colombia , Nov. 25, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTC: PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the three- and nine-month periods ended September 30, 2019 .

  • PharmaCielo Announces RSU Grant
    CNW Group

    PharmaCielo Announces RSU Grant

    PharmaCielo Announces RSU Grant

  • PharmaCielo Announces Termination of Scheme Implementation Agreement with Creso Pharma
    CNW Group

    PharmaCielo Announces Termination of Scheme Implementation Agreement with Creso Pharma

    TORONTO , Nov. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) announces that earlier today it was advised by Creso Pharma Limited ("Creso Pharma") that due to BDO Corporate Finance (WA) Pty Ltd. changing its independent expert report to conclude that the PharmaCielo Share Scheme is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma, it is impossible for the Board of Directors of Creso Pharma to support the Share and Option Schemes (the "Schemes") in their current form. As a result of the Creso Pharma Board of Directors changing its recommendation in respect of the Schemes, PharmaCielo has terminated the Scheme Implementation Agreement (the "Scheme Implementation Agreement"), originally announced on June 6, 2019 , in accordance with its terms.

  • CNW Group

    PharmaCielo Trading Halted Pending Update from Creso Pharma

    TORONTO , Nov. 4, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that trading in its common shares was halted today, pending an update from Creso Pharma Limited ("Creso Pharma") in respect of PharmaCielo's proposed acquisition of the company, which was originally announced on June 6, 2019 . As outlined in a press release on November 1, 2019 , BDO Corporate Finance (WA) Pty Ltd. has updated its independent expert report dated September 26, 2019 , to conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the issued and outstanding shares of Creso Pharma, is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma.

  • PharmaCielo Provides Update on Proposed Acquisition of Creso Pharma
    CNW Group

    PharmaCielo Provides Update on Proposed Acquisition of Creso Pharma

    TORONTO , Nov. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that in respect of its proposed acquisition of Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019 , and prior to the opening of the markets this morning, the Company was advised that Creso Pharma had received a supplementary independent expert report from BDO Corporate Finance (WA) Pty Ltd. updating its September 26, 2019 report, to now conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the issued and outstanding shares of Creso Pharma, is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma. The PharmaCielo Board of Directors has communicated that while it remains committed to closing the proposed transaction with Creso Pharma in its current form and in a disciplined manner, it will not increase the consideration that has been offered to Creso Pharma shareholders and listed optionholders as part of the acquisition.

  • PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders
    CNW Group

    PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders

    PharmaCielo's acquisition of Creso Pharma will establish a global medicinal cannabis company, positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company. TORONTO , Oct. 2, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), is pleased to announce key developments in respect of its friendly acquisition of Australian Securities Exchange ("ASX") listed Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019 . Creso Pharma has informed the Company that it has received approval from the Supreme Court of Western Australia (the "Court") to convene meetings of its shareholders and listed optionholders (the "Meetings"), and if thought fit, to approve the Schemes of Arrangement whereby PharmaCielo would acquire all of the issued and outstanding shares and listed options of Creso Pharma (the "Schemes of Arrangement").

  • Benzinga

    Colombian Cannabis Cultivator PharmaCielo Enters US Market

    The company completed introductory shipments of its medical CBD isolate to multi-state distributor General Extract LLC. The CBD isolate shipments, compliant with the 2018 Farm Bill requirements, are part of a non-exclusive sales agreement between the two companies. As per the deal, PharmaCielo will provide bulk medicinal CBD isolate to be sold and distributed by General Extract across the U.S.

  • PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC
    CNW Group

    PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

    PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

  • PharmaCielo Announces Financial Results for the Second Quarter 2019
    CNW Group

    PharmaCielo Announces Financial Results for the Second Quarter 2019

    PharmaCielo Announces Financial Results for the Second Quarter 2019

  • PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe
    CNW Group

    PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe

    TORONTO and CHAM, Switzerland , Aug. 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully completed the first commercial export of CBD isolate to Europe . The inaugural shipment of the high quality CBD isolate, a key ingredient in various cannabis derived therapeutic, nutraceutical, topicals and lifestyle products, was delivered to the Swiss headquarters of Creso Pharma, a global pharmaceutical with expertise in cannabis- and hemp-derived products for human and veterinarian use. This comes on the heels of the Colombian government granting the first commercial CBD isolate exporting permit to PharmaCielo, as announced on July 25, 2019 .

  • Benzinga

    PharmaCielo Announces Expansion In Latin America Through Veterinary CBD Partnership

    Canada-based PharmaCielo Ltd (OTC: PHCEF ), one of the largest cannabis companies operating in Colombia, announced this week it's teaming up with Uruguay-based Laboratorios Adler to supply the latter with ...

  • PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler
    CNW Group

    PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler

    TORONTO and MONTEVIDEO, Uruguay , Aug. 13, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced it has signed a sales agreement with Uruguay -based Laboratorios Adler ("Adler"). According to the agreement, PharmaCielo will provide Adler with bulk CBD extracts, bulk and bottled CBD oils and veterinary products that will be sold by Adler in Uruguay , Paraguay , Bolivia and Southern Brazil .

  • PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative
    CNW Group

    PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative

    TORONTO and RIONEGRO, Colombia , Aug. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joined the TruTrace Technologies, Inc. ("TruTrace") (CSE:TTT, OTCQB:TTTSF) and Shoppers Drug Mart initiated medical cannabis pilot verification program ("Pilot Program").

  • PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

  • PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts
    CNW Group

    PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts

    TORONTO and RIONEGRO, Colombia , Aug. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is ramping up its oil processing capabilities in the Company's Rionegro, Colombia facility following the recent acquisition and installation of additional high-performance, high-volume extractors, combined with proprietary extraction techniques.

  • Benzinga

    The Cannabis Sustainability Inquiry: Could Marijuana And Hemp Offer The Solution To The World's Toughest Environmental, Social, And Economic Problems?

    As a nascent (legal) consumer industry, the cannabis industry has a chance to invent itself from the ground up in the image of modern-day social, economic, and environmental sustainability. In March 2020 the United Nations is set to vote on what may be the termination of a half-Century of Treaty ban on Cannabis medicines. The World Health Organization is actively in the process of unprecedented scientific assessment of Cannabis, cannabinoids and Cannabis derivatives to begin to separate global stigma of the plant from the potential, its truly untapped medicinal, health-oriented public benefits.

  • PharmaCielo Completes Acquisition of Ubiquo Telemedicina
    CNW Group

    PharmaCielo Completes Acquisition of Ubiquo Telemedicina

    TORONTO , July 26, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed the acquisition of all of the shares (the "Acquisition") of Ubiquo Telemedicina S.A.S. ("Ubiquo Telemedicina"), previously announced on April 20, 2018 .

  • PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate
    CNW Group

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

  • PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer

    RIONEGRO, Colombia , July 22, 2019 /CNW/ - PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the "Company"), the premier cultivator and producer of medicinal-grade cannabis oils and extracts in Colombia and subsidiary of Canadian firm PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF), is pleased to announce the appointment of Andres Felipe Botero as Chief Operations Officer (COO).

  • Benzinga

    From Coffee To Cannabis: Colombia's Choice Between Economic Development And 'CannaMercantilism'

    This is the second of a two-part series on the history of Colombia’s troubled past and how it has informed its route to cannabis legalization. Mr. Azadian replied, “We were frustrated with many things in the marketplace including product inconsistency, quality control standards, inefficiencies, high costs of products and environmentally unsustainable operations.

  • PharmaCielo Announces Trading on the OTC Market
    CNW Group

    PharmaCielo Announces Trading on the OTC Market

    TORONTO and RIONEGRO, Colombia , June 21, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO) (OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it is trading on the OTC Markets under the symbol "PHCEF". "With our recently announced acquisition agreement with Creso Pharma (CPH.AX) there is increased attention and interest in our stock. Trading on the OTC will increase access for U.S. and international investors, providing greater liquidity and better access to capital. As we move forward building a global medicinal cannabis company, we will work to provide easy access and liquidity for investors in all jurisdictions," said David Attard , Chief Executive Officer of PharmaCielo Ltd.

  • PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million
    CNW Group

    PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million

    TORONTO , June 6, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has entered into a scheme implementation agreement (the "Implementation Agreement") pursuant to which PharmaCielo has agreed to acquire all of the issued and outstanding shares and listed options of Creso Pharma Ltd. ("Creso Pharma") (CPH.AX), for an aggregate purchase price of approximately A$122 million (the "Acquisition").  Creso Pharma is a global medicinal cannabis company that specializes in research, development and production of therapeutic, nutraceutical and animal health products. PharmaCielo will pay A$0.63 per Creso Pharma share, representing a premium of 50% over the closing trading price of the Creso Pharma shares on May 31 , 2019.

  • PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor
    PR Newswire

    PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor

    TORONTO, May 29, 2019 /PRNewswire/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it has enlisted former U.S. congressman and long-time medical cannabis advocate Dana Rohrabacher as a special advisor to the Company.